Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1151-1158

  Dial, Sandra ^a   Nessim, Sharon J ^a   Kezouh, Abbas ^b   Benisty, Jacques ^b   Suissa, Samy ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; hypertension; renal failure; sepsis; telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SEPSIS; SEPTICEMIA; DRUG EFFECTS; FACTUAL DATABASE; RISK; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84919346579     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12419     Document Type: Article

References (33)

1. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P,. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183.
2. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW,. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008; 7: 875-884.
3. FDA clinical review: NDA 20-850 efficacy supplement SE1-025, micardis (telmisartan) tablets. 29-7- 2009. Ref Type: Online Source.
4. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P,. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-1847.
5. Doerschug KC, Delsing AS, Schmidt GA, Ashare A,. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 2010; 14: R24.
6. Lund DD, Brooks RM, Faraci FM, Heistad DD,. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 2007; 293: H3726-H3731.
7. Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A,. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol Scand 2004; 48: 198-204.
8. Wan L, Langenberg C, Bellomo R, May CN,. Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13: R190.
9. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ,. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007; 27: 1619-1626.
10. Jick H, Jick SS, Derby LE,. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-768.
11. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H,. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
12. Walley T, Mantgani A,. The UK general practice research database. Lancet 1997; 350: 1097-1099.
13. Jen MH, Holmes AH, Bottle A, Aylin P,. Descriptive study of selected healthcare-associated infections using national Hospital Episode Statistics data 1996-2006 and comparison with mandatory reporting systems. J Hosp Infect 2008; 70: 321-327.
14. Aylin P, Bottle A, Majeed A,. Use of administrative data or clinical databases as predictors of risk of death in hospital: comparison of models. BMJ 2007; 334: 1044-1047.
15. Martin G, Mannino D, Eaton S, Moss M,. The Epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
16. Hackam DG, Mamdani M, Li P, Redelmeier DA,. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-418.
17. Melamed A, Sorvillo FJ,. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009; 13: R28.
18. ICD-10-CM official guidelines for coding and reporting. 2014. Ref Type: Online Source.
19. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F,. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
20. Delaney JA, Moodie EE, Suissa S,. Validating the effects of drug treatment on blood pressure in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008; 17: 535-545.
21. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S,. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-1785.
22. Angus DC, Pereira CA, Silva E,. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006; 6: 207-212.
23. Machado FR, Mazza BF,. Improving mortality in sepsis: analysis of clinical trials. Shock 2010; 34 (Suppl. 1): 54-58.
24. Bernard C, Merval R, Esposito B, Tedgui A,. Resistance to endotoxin shock in spontaneously hypertensive rats. Hypertension 1998; 31: 1350-1356.
25. Nunes JP,. Effects of lipopolysaccharide on vascular reactivity and mortality in rats. Auton Autacoid Pharmacol 2002; 22: 247-252.
26. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J,. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000; 15: 347-353.
27. Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Kramer BK,. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol 2000; 53: 486-488.
28. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ,. Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006; 61: 211-220.
29. Shrank WH, Patrick AR, Alan BM,. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011; 26: 546-550.
30. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP,. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19: 607-613.
31. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG,. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193-1200.
32. Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E,. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011; 22: 125-133.
33. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J,. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-596.